View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2013	Aug. 05, 2013
Document and Entity Information
Entity Registrant Name	Sunshine Heart, Inc.
Entity Central Index Key	0001506492
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		12,384,890
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 21,526	$ 14,224
Other current assets	704	333
Total current assets	22,230	14,557
Property, plant and equipment, net	413	479
TOTAL ASSETS	22,643	15,036
Current liabilities
Accounts payable	1,324	1,156
Accrued salaries, wages, and other compensation	926	931
Total current liabilities	2,250	2,087
Total liabilities	2,250	2,087
Commitments and contingencies
Stockholders' equity
Preferred Stock as of June 30, 2013 and December 31, 2012, par value $0.0001; per share; authorized 40,000,000 shares
Common stock as of June 30, 2013 and December 31, 2012, par value $0.0001 per share; authorized 100,000,000 shares: issued and outstanding 12,384,867 and 9,282,724 shares, respectively	1	1
Additional paid-in capital	107,005	91,017
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,260	1,185
Accumulated deficit	(87,873)	(79,254)
Total stockholders' equity	20,393	12,949
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 22,643	$ 15,036

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2013	Dec. 31, 2012
Condensed Consolidated Balance Sheets
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	40,000,000	40,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,384,867	9,282,724
Common stock, shares outstanding	12,384,867	9,282,724

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Condensed Consolidated Statements of Operations and Comprehensive Loss
Net sales	$ 0		$ 0
Operating expenses
Selling, general and administrative	2,150	$ 1,569	4,126	$ 3,509
Research and development	3,150	1,787	5,576	3,953
Total operating expenses	5,300	3,356	9,702	7,462
Loss from operations	(5,300)	(3,356)	(9,702)	(7,462)
Interest income	3	4	6	29
Loss before income taxes	(5,297)	(3,352)	(9,696)	(7,433)
Income tax benefit	(1,077)	(730)	(1,077)	(730)
Net loss	$ (4,220)	$ (2,622)	$ (8,619)	$ (6,703)
Basic and diluted loss per share (in dollars per share)	$ (0.35)	$ (0.42)	$ (0.81)	$ (1.08)
Weighted average shares outstanding - basic and diluted (in shares)	11,911	6,277	10,664	6,223
Comprehensive loss	$ (4,137)	$ (2,610)	$ (8,544)	$ (6,640)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Condensed Consolidated Statements of Cash Flows
Net loss	$ (8,619)	$ (6,703)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	83	63
Loss on disposal of plant and equipment		63
Stock-based compensation expense	838	621
Amortization of warrants for service agreements	240
Changes in assets and liabilities
Other current assets	(371)	(286)
Accounts payable and accrued expenses	258	(573)
Net cash used in operations	(7,571)	(6,815)
Cash flows used in investing activities:
Purchases of property and equipment	(17)	(107)
Net cash used in investing activities	(17)	(107)
Cash flows provided by financing activities:
Net proceeds from the sale of common stock	14,910	2,068
Net cash provided by financing activities	14,910	2,068
Effect of exchange rate changes in cash	(20)	63
Net decrease in cash and cash equivalents	7,302	(4,791)
Cash and cash equivalents - beginning of period	14,224	6,563
CASH AND CASH EQUIVALENTS - END OF PERIOD	$ 21,526	$ 1,772

Nature of Business and Significant Accounting Policies	6 Months Ended
Nature of Business and Significant Accounting Policies	Jun. 30, 2013
Nature of Business and Significant Accounting Policies
Nature of Business and Significant Accounting Policies	Note 1 - Nature of Business and Significant Accounting Policies Nature of Business: Sunshine Heart (*“we”* or the *“Company”) was founded in November 1999 and incorporated in Delaware in August 2002. The Company’s headquarters are located in Eden Prairie, MN and the Company also has a wholly owned subsidiary, Sunshine Heart Company Pty Ltd, located in Clontarf, New South Wales, Australia. We are a medical device company developing innovative technologies for cardiac and coronary disease. The Company’s primary product, the C-Pulse® Heart Assist System, or C-Pulse Heart System, is an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure, which can be implanted using a minimally invasive procedure. The C-Pulse Heart System is designed to relieve the symptoms of heart failure through the use of counterpulsation technology by enabling an increase in cardiac function, an increase in coronary blood flow, and a reduction in the heart’s pumping load. The Company received approval from the U.S. Food and Drug Administration, or FDA, to conduct a U.S. pivotal clinical trial with the C-Pulse Heart System. Our shares of common stock in the form of CHESS Depositary Interests, or CDIs, were publicly traded in Australia on the Australian Securities Exchange, or ASX, from September 2004 until our delisting from the ASX, effective May 6, 2013. Going Concern:* The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2012 and 2011 and through June 30, 2013, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2012, we had an accumulated deficit of $79,254 and we expect to incur losses for the foreseeable future. To date, the Company has been funded by private and public equity financings. Although we believe that we will be able to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably. The Company’s ability to continue as a going concern is dependent on the Company’s ability to raise additional capital based on the achievement of existing milestones as and when required. Should the future capital raising not be successful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern. Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, *“Sunshine Heart”* or the *“Company”). All intercompany accounts and transactions between consolidated entities have been eliminated. Unaudited Interim Condensed Consolidated Financial Information:* The interim condensed consolidated balance sheet as of June 30, 2013 and statementof operations for the three and six month periods ended June 30, 2013 and 2012, as well as the statement of cash flows for the six months ended June 30, 2013 and 2012 and related interim information contained in the notes to these financial statements are unaudited. The accompanying condensed consolidated financial statements have been prepared in accordance with Regulation S-X of the Securities Act of 1933, as amended. In the opinion of management, such unaudited interim condensed consolidated information has been prepared in accordance with accounting principles generally accepted in the United States (*“U.S. GAAP”) and includes all adjustments consisting of normal recurring accruals necessary for the fair presentation of this interim condensed consolidated information when read in conjunction with the audited consolidated financial statements and notes thereto. Certain information and disclosures normally included in the consolidated financial statements have been condensed or omitted pursuant to such rules and regulations, although management believes that disclosures are adequate to make information presented not misleading. Results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or any other interim period or for any other future year. Use of Estimates:* The preparation of interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the interim condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share (“EPS”) is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 3,247,311 and 2,457,291 for the six months ended June 30, 2013 and 2012, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods. Fair Value of Financial Instruments: Our financial instruments consist of cash, accounts payable and accrued liabilities. We believe that the carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities. Pursuant to the requirements of the Financial Accounting Standards Board (*“FASB”), Audit Standards Codification (“ASC”) Topic 820, Fair Value Measurement, the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges. Level 2: Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques. All cash and cash equivalents are considered Level 1 measurements for all periods presented. We do not have any financial instruments classified as Level 2 or Level 3 and there were no movements between these categories. Recent Accounting Pronouncements:* In February 2013, the FASB issued guidance adding new disclosure requirements for items reclassified out of accumulated other comprehensive income (*“AOCI”), which became effective for us on January 1, 2013. The guidance is intended to help entities improve the transparency of changes in other comprehensive income (“OCI”*) and items reclassified out of AOCI in financial statements. It does not amend any existing requirements for reporting net income or OCI in financial statements. The implementation of the guidance did not have a material impact on our consolidated financial statements.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

Equity	6 Months Ended
Equity	Jun. 30, 2013
Equity
Equity	Note 2 — Equity Common Stock Purchase Agreement On January 15, 2013, we entered into a Common Stock Purchase Agreement (the *“Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $25.0 million in shares of our common stock (the “Purchase Shares”) over a two-year period at purchase prices determined in accordance with the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, we have filed and maintain a registration statement on Form S-1 with the SEC under which we have registered 3,000,000 shares of our common stock for resale by Aspire Capital. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, we issued to Aspire Capital 80,257 shares of our common stock as a commitment fee (the “Commitment Shares”). The Purchase Agreement provides that we may not issue and sell more than 1,856,616 shares, or 19.99% of the Company’s outstanding shares as of January 15, 2013. As of June 30, 2013, we have sold 146,886 shares of common stock to Aspire Capital pursuant to the Purchase Agreement. Including the Commitment Shares, an aggregate of 227,143 shares of common stock have been issued to Aspire Capital pursuant to the Purchase Agreement. The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions by, among and for the benefit of the parties. The Purchase Agreement may be terminated by us at any time, at our discretion, without any cost or penalty to us. Aspire Capital has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares. We did not pay Aspire Capital any expense reimbursement in connection with the transaction. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. Public Offering* On April 16, 2013 we sold 2,875,000 shares of common stock in a public offering at $5.25 per share including 375,000 shares of common stock pursuant to the exercise of the over-allotment option by our underwriters. Proceeds in the public offering and exercise of the over-allotment option, net of transaction costs were $14,036 in the aggregate. Stock-Based Compensation The Company recognizes all share-based payments, including grants of stock options and compensatory employee stock purchase plans, in the income statement as an operating expense, based on their fair value over the requisite service period. We recorded $483 and $174 of related compensation expense to selling, general and administrative expense and research and development expense, respectively, for the three months ended June 30, 2013, as compared to $196 and $107, respectively, of related compensation expense for the three months ended June 30, 2012.We recorded $603 and $286 of related compensation expense to selling, general and administrative expense and research and development expense, respectively, for the six months ended June 30, 2013, as compared to $402 and $219, respectively, of related compensation expense for the six months ended June 30, 2012. As of June 30, 2013, a total of $5,106 of unrecognized compensation costs related to non-vested stock option awards was outstanding and is expected to be recognized within the next 3.8 fiscal years. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The volatility factor used in the Black-Scholes option pricing model is based on historical stock price fluctuations. The current forfeiture rate is based on a reasonable estimate by management. Expected dividend yield is based upon the Company’s historical and projected dividend activity and the risk free interest rate is based upon US Treasury rates appropriate for the expected term of the options. The expected term is based on estimates regarding projected employee stock option exercise behavior. The Company’s stock options generally vest over four years of service and have a contractual life of 10 years. We have 400,924 shares authorized for grant under our Amended and Restated 2011 Equity Incentive Plan and 195,000 shares authorized for grant under our 2013 Non-Executive Directors’ Equity Incentive Plan. Warrants Warrants to purchase 1,633,253 shares of common stock were outstanding at June 30, 2013 and December 31, 2012.

Balance Sheet Information

6 Months Ended

Jun. 30, 2013

Balance Sheet Information

Balance Sheet Information

Note 3 - Balance Sheet Information

Property, Plant and Equipment

Property, plant and equipment were as follows:

	June 30, 2013			December 31, 2012

Office Furniture & Fixtures	$	108		$	102
Leasehold Improvements	145			145
Software	13			12
Production Equipment	438			425
Computer Equipment	115			118
Total	819			802
Accumulated Depreciation	(406		)	(323		)
	$	413		$	479

Depreciation expense for the three and six months ended June 30, 2013 and 2012 was $43, $32, $ 83 and $63, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Nature of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2013
Nature of Business and Significant Accounting Policies
Nature of Business	Nature of Business: Sunshine Heart (*“we”* or the *“Company”*) was founded in November 1999 and incorporated in Delaware in August 2002. The Company’s headquarters are located in Eden Prairie, MN and the Company also has a wholly owned subsidiary, Sunshine Heart Company Pty Ltd, located in Clontarf, New South Wales, Australia. We are a medical device company developing innovative technologies for cardiac and coronary disease. The Company’s primary product, the C-Pulse® Heart Assist System, or C-Pulse Heart System, is an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure, which can be implanted using a minimally invasive procedure. The C-Pulse Heart System is designed to relieve the symptoms of heart failure through the use of counterpulsation technology by enabling an increase in cardiac function, an increase in coronary blood flow, and a reduction in the heart’s pumping load. The Company received approval from the U.S. Food and Drug Administration, or FDA, to conduct a U.S. pivotal clinical trial with the C-Pulse Heart System. Our shares of common stock in the form of CHESS Depositary Interests, or CDIs, were publicly traded in Australia on the Australian Securities Exchange, or ASX, from September 2004 until our delisting from the ASX, effective May 6, 2013.
Going Concern	Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2012 and 2011 and through June 30, 2013, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2012, we had an accumulated deficit of $79,254 and we expect to incur losses for the foreseeable future. To date, the Company has been funded by private and public equity financings. Although we believe that we will be able to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably. The Company’s ability to continue as a going concern is dependent on the Company’s ability to raise additional capital based on the achievement of existing milestones as and when required. Should the future capital raising not be successful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.
Basis of Presentation	Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, *“Sunshine Heart”* or the *“Company”*). All intercompany accounts and transactions between consolidated entities have been eliminated.
Unaudited Interim Consolidated Financial Information	Unaudited Interim Condensed Consolidated Financial Information: The interim condensed consolidated balance sheet as of June 30, 2013 and statementof operations for the three and six month periods ended June 30, 2013 and 2012, as well as the statement of cash flows for the six months ended June 30, 2013 and 2012 and related interim information contained in the notes to these financial statements are unaudited. The accompanying condensed consolidated financial statements have been prepared in accordance with Regulation S-X of the Securities Act of 1933, as amended. In the opinion of management, such unaudited interim condensed consolidated information has been prepared in accordance with accounting principles generally accepted in the United States (*“U.S. GAAP”*) and includes all adjustments consisting of normal recurring accruals necessary for the fair presentation of this interim condensed consolidated information when read in conjunction with the audited consolidated financial statements and notes thereto. Certain information and disclosures normally included in the consolidated financial statements have been condensed or omitted pursuant to such rules and regulations, although management believes that disclosures are adequate to make information presented not misleading. Results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or any other interim period or for any other future year.
Use of Estimates	Use of Estimates: The preparation of interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the interim condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Net Loss per Share	Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share (“EPS”) is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 3,247,311 and 2,457,291 for the six months ended June 30, 2013 and 2012, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods.
Fair Value of Financial Instruments	Fair Value of Financial Instruments: Our financial instruments consist of cash, accounts payable and accrued liabilities. We believe that the carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities. Pursuant to the requirements of the Financial Accounting Standards Board (*“FASB”), Audit Standards Codification (“ASC”*) Topic 820, Fair Value Measurement, the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges. Level 2: Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques. All cash and cash equivalents are considered Level 1 measurements for all periods presented. We do not have any financial instruments classified as Level 2 or Level 3 and there were no movements between these categories.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: In February 2013, the FASB issued guidance adding new disclosure requirements for items reclassified out of accumulated other comprehensive income (*“AOCI”), which became effective for us on January 1, 2013. The guidance is intended to help entities improve the transparency of changes in other comprehensive income (“OCI”*) and items reclassified out of AOCI in financial statements. It does not amend any existing requirements for reporting net income or OCI in financial statements. The implementation of the guidance did not have a material impact on our consolidated financial statements.

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References + Details

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Apr. 16, 2013	Jan. 15, 2013	Jun. 30, 2013	Jun. 30, 2012
Public Offering
Proceeds, net of transaction costs			$ 14,910	$ 2,068
Common stock purchase agreement
Common Stock Purchase Agreement
Common stock sold (in shares)	2,875,000
Public Offering
Common stock sold (in shares)	2,875,000
Common stock offering price (in dollars per share)	$ 5.25
Shares issued upon exercise of over-allotment options by underwriters	375,000
Proceeds, net of transaction costs	$ 14,036
Common stock purchase agreement \| Aspire Capital
Common Stock Purchase Agreement
Term for purchase of shares by Aspire Capital		2 years
Number of shares of common stock registered on Form S-1 for resale by Aspire		3,000,000
Number of shares of common stock issued to Aspire Capital as commitment fee		80,257
Common stock sold (in shares)			146,886
Common stock sold including commitment shares (in shares)			227,143
Public Offering
Common stock sold (in shares)			146,886
Maximum \| Common stock purchase agreement \| Aspire Capital
Common Stock Purchase Agreement
Value of common stock purchase commitment		$ 25,000
Number of shares authorized for sale and issuance (in shares)		1,856,616
Shares authorized for sale and issuance (as a percent)		19.99%

Equity (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Equity (Details 2) - USD ($) $ in Thousands	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Stock-Based Compensation
Unrecognized compensation costs related to non-vested stock option awards	$ 5,106		$ 5,106
Unrecognized compensation costs related to non-vested stock option awards, recognition period			3 years 9 months 18 days
Vesting period of options			4 years
Contractual life of options			10 years
Warrants
Number of shares of common stock that outstanding warrants can purchase (in shares)	1,633,253		1,633,253		1,633,253
Amended and Restated 2011 Equity Incentive Plan
Stock-Based Compensation
Shares authorized for grant	400,924		400,924
2013 Non-Executive Directors' Equity Incentive Plan
Stock-Based Compensation
Shares authorized for grant	195,000		195,000
Selling, general and administrative expense
Stock-Based Compensation
Compensation expense	$ 483	$ 196	$ 603	$ 402
Research and development expense
Stock-Based Compensation
Compensation expense	$ 174	$ 107	$ 286	$ 219

Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment
Total	$ 819		$ 819		$ 802
Accumulated Depreciation	(406)		(406)		(323)
Property, plant and equipment, net	413		413		479
Depreciation expense	43	$ 32	83	$ 63
Office Furniture & Fixtures
Property, Plant and Equipment
Total	108		108		102
Leasehold Improvements
Property, Plant and Equipment
Total	145		145		145
Software
Property, Plant and Equipment
Total	13		13		12
Production Equipment
Property, Plant and Equipment
Total	438		438		425
Computer Equipment
Property, Plant and Equipment
Total	$ 115		$ 115		$ 118

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2013
Income Taxes
Income Taxes	Note 4 — Income Taxes We received a $1,077 research and development tax credit refund in the quarter ended June 30, 2013, based upon qualified research and development expenditures of our Australian subsidiary for its tax period ended June 30, 2012. We received a $730 research and development tax credit refund in the quarter ended June 30, 2012 based upon qualified research and development expenditures of our Australian subsidiary for its tax period ended June 30, 2011. We have not completed the Australian tax return for the period ended June 30, 2013; therefore, we have not reflected a benefit related to the Australian research and development tax credit for that period as we recognize any benefit only upon receipt.

Nature of Business and Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Going Concern
Accumulated deficit	$ 87,873	$ 79,254

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Taxes
Tax credit	$ 1,077	$ 730	$ 1,077	$ 730

Nature of Business and Significant Accounting Policies (Details 2) - shares	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Antidilutive securities
Shares reserved for outstanding stock warrants and options excluded from the computation of loss per share due to their antidilutive effect	3,247,311	2,457,291